Učitavanje...
Regorafenib in hepatocellular carcinoma: latest evidence and clinical implications
Over the past ten years, sorafenib, a multikinase inhibitor, has been the only systemic agent approved for first-line treatment of patients with unresectable hepatocellular carcinoma (HCC). Whereas only recently lenvatinib was shown to be noninferior to sorafenib, in terms of survival, all other age...
Spremljeno u:
| Izdano u: | Drugs Context |
|---|---|
| Glavni autori: | , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
BioExcel Publishing Ltd
2018
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6038776/ https://ncbi.nlm.nih.gov/pubmed/30002715 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7573/dic.212533 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|